Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.49 |
| ▸ | PARP1 | P09874 | 6/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Noroxyhydrastinine SCHEMBL29745981 | 1.00 | KDM4E (1.00) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL30142226 | 0.81 | KDM4E (0.69) | KDM4EPARP1ACHECYP2D6GRM5 | |
| SCHEMBL12745699 | 0.78 | KDM4E (0.63) | KDM4EPARP10PARP11ACHECYP2D6 | |
| SCHEMBL9739665 | 0.75 | KDM4E (0.60) | KDM4EPARP10PARP11PARP1ACHE | |
| SCHEMBL9739248 | 0.75 | KDM4E (0.59) | KDM4EPARP10PARP11PARP1F7 | |
| SCHEMBL6488098 | 0.74 | KDM4E (0.59) | KDM4EACHECYP2D6 | |
| SCHEMBL6488102 | 0.74 | KDM4E (0.59) | KDM4EACHECYP2D6 | |
| SCHEMBL6488092 | 0.74 | KDM4E (0.59) | KDM4EACHECYP2D6 | |
| SCHEMBL5568453 | 0.73 | KDM4E (0.58) | KDM4ECYP2D6 | |
| SCHEMBL6336267 | 0.73 | KDM4E (0.58) | KDM4EACHECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KP) | 2021-12-16 | — | — | US | disclosed |
| WO-2019008441-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2019-01-10 | — | — | WO | disclosed |
| CN-102908341-A | Vitexicarpin used as pharmaceutical active ingredient with anti-angiogenesis function | UNIV TSINGHUA | 2013-02-06 | — | — | CN | disclosed |
| CN-102030812-B | Timosaponin A-III serving as medicinal active ingredient with angiogenesis resistance | UNIV TSINGHUA | 2012-07-04 | — | — | CN | disclosed |
| US-20120035855-A1 | METHOD OF NETWORK-BASED IDENTIFICATION FOR DRUG ACTION AND/OR SYNERGY EFFECT OF MEDICINE COMBINATION | TSINGHUA UNIVERSITY | 2012-02-09 | — | — | US | disclosed |
| EP-2369493-A1 | GENE NETWORK-BASED METHOD FOR CONFIRMING DRUG ACTION | Tsinghua University (CN) | 2011-09-28 | — | — | EP | disclosed |
| CN-102030812-A | Timosaponin A-III serving as medicinal active ingredient with angiogenesis resistance | UNIV TSINGHUA | 2011-04-27 | — | — | CN | disclosed |
| CN-102028679-A | Vitexin as active ingredient of medicine with anti-angiogenesis effect | UNIV TSINGHUA | 2011-04-27 | — | — | CN | disclosed |
| US-20110086872-A1 | Berberine as a selective lung cancer agent and other compositions and methods | TIN-WA MAUNG | 2011-04-14 | — | — | US | disclosed |
| US-20070298132-A1 | Berberine as a selective lung cancer agent | PHARMCHEM INC. (US) | 2007-12-27 | — | — | US | disclosed |
| EP-0292840-B1 | Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | EP | disclosed |
| US-5175157-A | Cardiovascular disorders | BOEHRINGER INGELHEIM GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
| EP-0292840-A2 | Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | KDM4E 3750/4885PARP10 3044/4885PARP11 3705/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | KDM4E 3750/4885PARP10 3044/4885PARP11 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.